Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mazdutide (IBI362) in Chinese T2D Patients With Poor Glycemic Control (Diet/Exercise)
NCT05628311Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2023
- Primary completion
- Oct 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mazdutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Innovent Biologics. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Jan 2023; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05628311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628311.